Treating alpha-1-antitrypsin deficiency – pro
Alpha1-Proteinase Inhibitor (Human), Prolastin (alpha) is FDA indicated for chronic replacement therapy of individuals having congenital deficiency of alpha1-PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Aralast is a similar drug. Studies of Aralast and Zemaira have shown equivalency with Prolastin in achieving and maintaining alpha1-antitrypsin serum levels and alveolar epithelial levels above the target level.
Read more